My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

5.900 -0.080 (-1.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Why Plug Power Is Trading Higher By Around 14%, Here Are 73 Stocks Moving In Wednesday's Mid-Day Session
Gainers BioAtla, Inc. (NASDAQ: BCAB) gained 50.1% to $5.42 following Q2 results. Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 39.5% to $2.0380. 
Via Benzinga
Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving Premarket
Gainers ObsEva SA (NASDAQ: OBSV) shares rose 33.8% to $0.4080 in pre-market trading. ObsEva recently announced a $31 million debt retirement and $11 million debt refinancing. 
Via Benzinga
Recap: AbCellera Biologics Q1 Earnings
AbCellera Biologics (NASDAQ:ABCL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
AbCellera Reports Q2 2022 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
From AbCellera Biologics Inc.
Via Business Wire
Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
From AbCellera Biologics Inc.
Via Business Wire
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Biologics's Return On Capital Employed Insights
According to Benzinga Pro, during Q1, AbCellera Biologics (NASDAQ:ABCL) earned $168.57 million, a 181.2% increase from the preceding quarter. AbCellera Biologics also posted a total of $316.58 million... 
Via Benzinga
Cramer Shares His Thoughts On Stem, Marvell Technology And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology Inc (NASDAQ: MRVL) is the "best when it comes to 5G, the best in high-performance computing. 
Via Benzinga
What 4 Analyst Ratings Have To Say About AbCellera Biologics
Over the past 3 months, 4 analysts have published their opinion on AbCellera Biologics (NASDAQ:ABCL) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
AbCellera Reports Q1 2022 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022
From AbCellera Biologics Inc.
Via Business Wire
3 Biotech Stocks Under $10 to Add to Your Buy List
These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. 
Via InvestorPlace
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Full Year 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools
From AbCellera Biologics Inc.
Via Business Wire
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Lilly's Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19
The FDA on Friday authorized Eli Lilly And Co's (NYSE: LLY) COVID-19 antibody drug for people aged 12 and older at risk of severe illness. The FDA authorized... 
Via Benzinga
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
From AbCellera Biologics Inc.
Via Business Wire
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
From AbCellera
Via Business Wire
Top Biotech Stocks: Trading Opportunities For Next Week
A security pattern traces the distinct movements of prices, which helps traders make informed trading decisions. Let's look at some biotech stock opportunities by analyzing these patterns. 
Via Talk Markets
AbCellera Announces Changes to Its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
Futures Rebound From Friday Rout As Omicron Fears Ease
S&P futures and European stocks rebounded from Friday’s selloff while Asian shares fell, as investors took comfort in reports from South Africa which said initial data doesn’t show a surge of... 
Via Talk Markets
Topics Stocks
Lilly's COVID-19 Antibody Cocktail Scores FDA Emergency Use For Kids, Including Newborns
The FDA has expanded the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) bamlanivimab and etesevimab administered together to include... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.